Researchers at Kyoto University Hospital have officially commenced Phase 1 human clinical trials for a revolutionary intravenous drug designed to regenerate lost teeth. The experimental therapy, developed by Toregem BioPharma, marks a historic milestone in regenerative medicine, potentially ending the global reliance on synthetic implants and dentures.
